Next-generation therapeutics for glioblastoma: Challenges and future directions
- 1Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; Department of Neurology, University of Miami, Miami, FL, USA
- 2Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
- 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; Department of Neurology, University of Miami, Miami, FL, USA; Corresponding author.
Abstract
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Although recent World Health Organization classifications integrating molecular features have improved diagnostic precision, therapeutic outcomes for IDH-wild-type glioblastoma remain dismal. Standard treatment with radiotherapy and temozolomide has changed little over the past two decades, and most investigational therapies have failed to produce durable clinical benefit. Tumor heterogeneity, adaptive resistance mechanisms, a profoundly immunosuppressive tumor microenvironment, and limited drug delivery across the blood–brain barrier have collectively contributed to these failures. This review summarizes the evolving molecular landscape of glioblastoma and examines emerging therapeutic approaches designed to overcome these barriers. We discuss advances in molecularly targeted therapies, including strategies directed at BRAF and FGFR alterations, as well as continued efforts to address EGFR-driven disease. We also review immunotherapeutic approaches such as immune checkpoint inhibition, chimeric antigen receptor T-cell therapies, and oncolytic viruses, highlighting key clinical trial results and biological challenges. In parallel, we explore metabolic targeting strategies and novel technologies aimed at improving central nervous system drug delivery, including focused ultrasound and convection-enhanced delivery. Collectively, current evidence indicates that meaningful progress in glioblastoma will require biomarker-driven patient selection, rational combination strategies, and improved methods for intracranial drug delivery. While substantial challenges remain, ongoing translational and clinical efforts provide a framework for the development of more effective and personalized therapeutic strategies.
Related
- Antibody Discovery and Therapeutics in Spondyloarthritis: Recent Advances and Future Directions.
- Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma.
- Traditional Chinese medicine (TCM)-based nanoformulations for cancer therapy: antitumor mechanisms, challenges, and future directions
- Brain-computer interfaces in pediatric populations: research advances, application challenges, and future directions
- Amivantamab and lazertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with brain and leptomeningeal metastases: an editorial on efficacy, challenges in assessment, and future directions.
BibTeX
@article{blaquier2026nextgeneration,
title = {{Next-generation therapeutics for glioblastoma: Challenges and future directions}},
author = {Juan B. Blaquier and Mary Jane Lim-Fat and Macarena de la Fuente},
journal = {Neurotherapeutics},
year = {2026},
month = oct,
doi = {10.1016/j.neurot.2026.e01050},
url = {https://doi.org/10.1016/j.neurot.2026.e01050},
note = {CC BY},
}
RIS
TY - JOUR
TI - Next-generation therapeutics for glioblastoma: Challenges and future directions
AU - Juan B. Blaquier
AU - Mary Jane Lim-Fat
AU - Macarena de la Fuente
PY - 2026
DA - 2026/10/24
JO - Neurotherapeutics
DO - 10.1016/j.neurot.2026.e01050
UR - https://doi.org/10.1016/j.neurot.2026.e01050
AB - Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Although recent World Health Organization classifications integrating molecular features have improved diagnostic precision, therapeutic outcomes for IDH-wild-type glioblastoma remain dismal. Standard treatment with radiotherapy and temozolomide has changed little over the past two decades, and most investigational therapies have failed to produce durable clinical benefit. Tumor heterogeneity, adaptive resistance mechanisms, a profoundly immunosuppressive tumor microenvironment, and limited drug delivery across the blood–brain barrier have collectively contributed to these failures. This review summarizes the evolving molecular landscape of glioblastoma and examines emerging therapeutic approaches designed to overcome these barriers. We discuss advances in molecularly targeted therapies, including strategies directed at BRAF and FGFR alterations, as well as continued efforts to address EGFR-driven disease. We also review immunotherapeutic approaches such as immune checkpoint inhibition, chimeric antigen receptor T-cell therapies, and oncolytic viruses, highlighting key clinical trial results and biological challenges. In parallel, we explore metabolic targeting strategies and novel technologies aimed at improving central nervous system drug delivery, including focused ultrasound and convection-enhanced delivery. Collectively, current evidence indicates that meaningful progress in glioblastoma will require biomarker-driven patient selection, rational combination strategies, and improved methods for intracranial drug delivery. While substantial challenges remain, ongoing translational and clinical efforts provide a framework for the development of more effective and personalized therapeutic strategies.
SN - 1878-7479
SN - 1933-7213
ER -